Merck & Co Inc. (NYSE:MRK) has entered an exclusive global license and collaboration agreement with Artiva Biotherapeutics for the development of chimeric antigen receptor (CAR) NK cell therapies for solid tumor-associated antigens. The agreement leverages...
